In response to COVID-19, we are currently limiting appointments at the KaRa MINDS site to only those people currently enrolled in our studies.
However, we continue to welcome enquiries and can assist you by registering your interest. In the meantime, stay well and we look forward to seeing you all soon.
At KaRa MINDS, we collaborate with international, national and local partners to prevent and treat neurological conditions such as Alzheimer's disease through research.
ANAVEX Study - Recruitment open
A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s disease.
ANAVEX Parkinson's disease dementia – Recruitment closed
A Phase 2, Double-blind, randomised, placebo-controlled study to evaluate the safety, tolerability and efficacy of ANAVEX2-73 for cognitive impairment in patients with Parkinson’s Disease with dementia.
XPRO Study - Recruiting
Phase 1b Open-Label, Dose-Identification Study of XPro1595 in Patients with Mild to Moderate Alzheimer’s Disease with Elevated high sensitivity C-reactive protein in Blood.
3D Study – Recruitment open
A Phase 2, Double-Blind, Randomized, Placebo-Controlled 52-week clinical proof of concept study for the treatment of Deferiprone to Delay Dementia
Clarity Study – Recruitment open
A Phase 3, Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study with an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects with Early Alzheimer’s Disease
EMBARK – Prior Engage study participants only
Phase 3b open-label, multicentre, safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies
Cerecin Study – Recruitment open
A Phase 3, Double-Blind, Randomised, Placebo-controlled 20-week Multiregional Clinical Trial of Tricaprilin in Mild to Moderately Severe Probable Alzheimer’s Disease
KARVIAH_XTND Study - Open to previous participants
Longitudinal investigational study examining blood, brain and lifestyle risk factors in an older at risk of AD population.
Retinal Study - Adjunct study only
Investigating the diagnostic utility of hyperspectral retinal imaging in preclinical Alzheimer’s disease
Mission AD Study
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer’s Disease.
A Phase II, Double -Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of XanamemTM in Subjects with Mild Dementia due to Alzheimer’s disease.
Biomarker qualification for risk of mild cognitive impairment due to Alzheimer’s disease and safety and efficacy evaluation of Pioglitazone in delaying its onset (TOMORROW)
A Phase 2b/3 randomised, double-blind, placebo-controlled, parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in subjects who are Asymptomatic and at risk for developing Alzheimer's disease.
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with early Alzheimer’s disease
A multinational, multi-center, randomized, double-blind, active comparator, phase III clinical trial to evaluate the efficacy and safety of donepezil transdermal patch in patients with Alzheimer’s disease.
Investigation of curcumin for the prevention of Alzheimer’s disease in cognitively healthy individuals, examining the blood, brain and retina.
TotAL Study - Recruitment via Macquarie University (Cognitively Healthy Males)
A 56 week, Double-Blind, Randomised Study to Evaluate the Efficacy of Testosterone, With and Without DHA Supplementation on Cerebral Amyloid Load in Known Brain Amyloid-PET Positive Men with Subjective Memory Complaints.
An open label, 12-week study to investigate the efficacy and safety of XPRO 1595 in Subjects with early-mod Alzheimer's disease.
For further details on any study, please call KaRa MINDS or use the Contact Us form at the bottom of the page and our friendly team will be in touch.